CRMD vs MRNA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRMD and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRMD and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CorMedix is a New Jersey-based pharmaceutical company whose lead product, DefenCath (taurolidine and heparin), is the first and only FDA-approved antimicrobial catheter lock solution in the United States. It prevents catheter-related bloodstream infections in adult hemodialysis patients who use a central venous catheter, a population where infections drive costly hospitalizations and mortality, and a Phase III study showed up to a 71% reduction in infection risk. After a 2023 approval, commercialization scaled quickly through multi-year agreements that now cover roughly 60% of the U.S. outpatient dialysis market, and DefenCath generated about ~$167.6M in 2025 sales.

Full CRMD guide

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CRMD drivers: DefenCath adoption in outpatient dialysis; Melinta platform diversification.
• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue is still heavily concentrated in DefenCath, so any adoption, contracting, or clinical setback would hit the whole story. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CRMD if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRMD and MRNA guides.

CRMD. CorMedix trades at a modest revenue multiple relative to many pre-profit biotech peers because it is already GAAP-profitable and EBITDA-positive, an unusual combination for a company only a couple of years into commercialization. Sell-side coverage skews constructive with an average 12-month target around ~$14.5, though price targets have drifted (for example RBC trimmed to ~$13 in mid-2026). The valuation debate centers on how durable DefenCath economics are once early reimbursement support fully rolls off.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

Headline figures (approximate, July 2026): CRMD shows q1 2026 revenue ~$127.4M, fy2026 revenue guidance ~$325M-$345M, q1 2026 net income ~$38.6M, q1 2026 adjusted ebitda ~$70M; MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%.

CRMD and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRMD and MRNA exposure against your real portfolio. It is not an investment adviser.